J Rheumatol: Phenylalanine is a new marker of advances in radioactive knee osteoarthritis

The study used a method of metabolitology to identify plasma markers associated with an increased risk of progression of radioactive knee osteoarthritis (OA)study participants from the Multicenter Osteoarthritis Study (MOST) were divided into two groups based on the presence of baseline radioactive OAThe subjects in group 1 had one-sided knee osteoarthritis, and group 2 subjects had bi-knee osteoarthritisProgress is defined as a 30-month follow-up when the width of joint clearance deteriorates by half degreesFor group 1, progress was shown when there was an imaging progressin of the OA knee and oA appeared in the lateral knee jointFor group 2, progress was shown when imaging progress was made in oA on both kneesA metological histology analysis of serum samples collected from the baseline was performed, and after adjusting age, sex, BMI and clinical sites, logistic regression was carried out to analyze the association between each metabolite and knee OA progressionanalysis included 234 participants (group 1 57 and group 2 177) and 322 non-progressives (group 1 206 and group 2 116)Of the 157 metabolites studied, the study found that in the joint analysis, the risk of progression increased by 1.46 times for every 1 standard deviation (SD) increase in phenylalanine levels (95% CI: 1.20-1.77, p.0001)Gender-specific analysis showed that levels of phenylanine in women were associated with risk of progression (p-0.0002), but not in menthis study data show that phenylalanine is a new type of plasma marker with an increased risk of progression in the female double-sided radiology knee OA